No more than 15 authors can be listed.Please ensure the authors are listed in the right order.If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.
Celecoxib combined with chemotherapy has failed to improve survival in non-small cell lung cancer (NSCLC) clinical trials. This study aimed to re-evaluate the therapeutic potential of celecoxib by investigating its dose-dependent effects on TGF-β1–induced epithelial–mesenchymal transition (EMT) in NSCLC cells.
NSCLC cells were treated with low-dose (2 μM) or high-dose (20 μM) celecoxib in the presence of TGF-β1. EMT-related molecular changes were analyzed using Western blotting and electric cell–substrate impedance sensing (ECIS). Phospho-kinase array analysis was performed to identify signaling pathways involved. STAT5b and AKT were knocked down or overexpressed to assess their functional roles in EMT regulation.
High-dose celecoxib significantly inhibited TGF-β1–induced EMT, as shown by increased E-cadherin expression and decreased mesenchymal markers and EMT-related transcription factors. In contrast, low-dose celecoxib enhanced TGF-β1–induced EMT. Phospho-kinase array analysis revealed differential activation of STAT5b and AKT depending on celecoxib concentration. Downregulation of STAT5b or AKT enhanced the inhibitory effect of high-dose celecoxib on EMT, whereas AKT overexpression promoted TGF-β1–induced EMT.
Celecoxib exerts dose-dependent and opposing effects on TGF-β1–induced EMT in NSCLC cells through STAT5b and AKT signaling pathways. These findings provide mechanistic insight into the inconsistent clinical efficacy of celecoxib and highlight the importance of dose selection in therapeutic strategies.